How to Cite
Abstract
Targeted therapy (lapatinib and/or trastuzumab) in combination with chemotherapy (capecitabine) is highly effective in metastatic lesions of the brain in breast cancer patients with overexpress HER-2/neu. An objective response in the brain was achieved in 19 patients (55.9%). Complete regression was observed in 5 cases (14.7%), partial regression — 14 (41.2%). Stabilization of tumor process in the brain was revealed in 12 patients (35.3%). There was marked improvement in the quality of life of the majority of patients due to the regression of symptoms and good tolerability of treatment.References
Москвина Е.А., Горбунова В.А., Насхлеташвили Д.Р. и др. Капецитабин в лечении метастатического поражения головного мозга у больных раком молочной железы // Опухоли головы и шеи. — 2012. — № 3. — С. 59-62.
Bachelot Th., Romieu G., Campone M. Dijras V. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study // Lancet Oncol. — 2013. — Vol. 14. — P 64-71.
Bartsch R., Berghoff A., Pluschnig U. et al. Systemic therapy and overall survival (OS) in patients (pts) with brain metastases from HER2-positive (HER2+) metastatic breast cancer (MBC) // J Clin Oncol. — 2011. — Vol. 29. — (suppl; abstr 597).
Bendell JC, Domchek SM, Burstein HJ, et al: Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma // Cancer. — 2003. — Vol. 97. — P. 2972-2977.
Bezjak A, Adam J, Barton R et al. Symptom response after palliative radiotherapy for patients with brain metastases // Eur J Cancer — 2002. — Vol. 38. — P 487-496.
Burstein HJ, Lieberman G, Slamon DJ et al. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy // Ann Oncol — 2005. — Vol. 16. — P. 1772-1777.
Chang E., Lob S. Diagnosis and Management of Central Nervous System Metastases from Breast Cancer // The Oncologist — 2003. — Vol. 8. — No. 5. — P. 398-410.
Christodoulou C, Bafaloukos D, Linardou H et al. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: A Hellenic Cooperative Oncology Group (HeCOG) phase II study // J Neurooncol — 2005. — Vol. 71. — P 61-65.
Cocconi G, Lottici R, Bisagni G et al. Combination therapy with platinum and etoposide of brain metastases from breast carcinoma // Cancer Invest — 1990. — Vol. 8. — P 327-334.
De la Monte SM, Hutchins GM, Moore GW: Estrogen and progesterone receptors in prediction of metastatic behavior of breast carcinoma // Am J Med 1984. — Vol. 76. — P. 11-17.
Fabi A, Vidiri A, Ferretti G et al. Dramatic regression of multiple brain metastases from breast cancer with capecitabine: Another arrow at the bow? // Cancer Invest — 2006. — Vol. 24. — P 466-468.
Franciosi V, Cocconi G, Michiara M et al., Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study // Cancer — 1999. — Vol. 85. — P. 1599-1605.
Heinrich B, Brudler O, Siekiera W, et al: Development of brain metastasis in metastatic breast cancer responding to treatment with trastuzumab // Proc Am Soc Clin Oncol — 2003. — Vol. 22. — P. 37 (abstr 147).
Hikino H, Yamada T, Johbara K et al. Potential role of chemo-radiation with oral capecitabine in a breast cancer patient with central nervous system relapse // Breast — 2006. — Vol. 15. — P 97-99.
Kirsch D.G., Ledezma C.J., Methews C.S. et al. Survival after brain metastases from breast cancer in the trastuzumab era // J Clin Oncol — 2005. — Vol. 23. — P. 2114-2116.
Khuntia D, Brown P, Li J et al. Whole-brain radiotherapy in the management of brain metastasis // J Clin Oncol — 2006. — Vol. 24. — P. 1295-1304.
Lin NU, Bellon JR, Winer EP CNS metastases in breast cancer // J Clin Oncol — 2004. — Vol. 22. — P. 3608-3617.
Lin NU, Carey LA, Liu MC et al. Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer // J Clin Oncol — 2006. — Vol. 24 (suppl 18). — P. 503a.
Oberhoff C, Kieback DG, Wurstlein R et al. Topotecan chemotherapy in patients with breast cancer and brain metastases: Results of a pilot study // Onkologie — 2001. — Vol. 24. — P. 256-260.
Park I., Ro J., Lee K., Nam B., et al. Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer // Ann Onc — 2008. — Vol. 10. — P 1093.
Rosner D, Flower A, Lane W. Chemotherapy induces regression of brain metastases in breast carcinoma patients: update study // Proc Am Soc Clin Oncol — 1993. — Vol. 12. — P. 508a.
Rosner D, Nemoto T, Lane WW. Chemotherapy induces regression of brain metastases in breast carcinoma // Cancer — 1986. — Vol. 58. — P 832-839.
Samaan NA, Buzdar AU, Aldinger KA, et al: Estrogen receptor: A prognostic factor in breast cancer // Cancer — 1981. — Vol. 47. — P 554-560.
Siegelmann-Danieli N, Stein M, Bar-Ziv J. Complete response of brain metastases originating in breast cancer to capecitabine therapy // Isr Med Assoc J — 2003. — Vol. 5. — P. 833-834.
Tsao MN, Lloyd N, Wong R et al. Whole brain radiotherapy for the treatment of multiple brain metastases // Cochrane Database Syst Rev — 2006. — Vol. 3. — CD003869.
Wang ML, Yung WK, Royce ME et al. Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer // Am J Clin Oncol — 2001. — Vol. 24. — P 421424.
Wardley AM, Danson S, Clayton AJ, et al: High incidence of brain metastases in patients treated with trastuzumab for metastatic breast cancer at a large cancer center // Proc Am Soc Clin Oncol — 2002. — Vol. — 21. — P. 61a, (abstr 241).
Weitzen R, Zach L, Kaufman B, et al: High incidence of brain metastasis in patients on trastuzumab for advanced breast cancer // Proc Am Soc Clin Oncol — 2002. — Vol. 21. — P 316 (abstr 1936).
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...